Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1993-9-16
pubmed:abstractText
A prospective trial was conducted involving 16 patients with colorectal adenocarcinoma using a regimen of continuous-infusion octreotide acetate (Sandostatin [octreotide acetate], Sandoz, East Hanover, NJ for the treatment of severe diarrhea induced by the weekly schedule of 5-fluorouracil (5-FU) in combination with leucovorin who were refractory to opiate therapy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
72
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1543-6
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed-meshheading:8348489-Adenocarcinoma, pubmed-meshheading:8348489-Adult, pubmed-meshheading:8348489-Aged, pubmed-meshheading:8348489-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:8348489-Colonic Neoplasms, pubmed-meshheading:8348489-Diarrhea, pubmed-meshheading:8348489-Female, pubmed-meshheading:8348489-Fluid Therapy, pubmed-meshheading:8348489-Fluorouracil, pubmed-meshheading:8348489-Humans, pubmed-meshheading:8348489-Infusions, Intravenous, pubmed-meshheading:8348489-Intestines, pubmed-meshheading:8348489-Leucovorin, pubmed-meshheading:8348489-Male, pubmed-meshheading:8348489-Middle Aged, pubmed-meshheading:8348489-Octreotide, pubmed-meshheading:8348489-Prospective Studies, pubmed-meshheading:8348489-Rectal Neoplasms, pubmed-meshheading:8348489-Recurrence, pubmed-meshheading:8348489-Remission Induction, pubmed-meshheading:8348489-Time Factors
pubmed:year
1993
pubmed:articleTitle
Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
pubmed:affiliation
Department of Surgical Oncology, Grace Cancer Drug Center, Roswell Park Cancer Institute, Buffalo, New York 14263.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.